RecruitingPhase 2ACTRN12616000520437

Evaluation of glyceryl trinitrate ointment as treatment for leg ulcers

A double blind (pilot) trial of the application of 0.2% glyceryl trinitrate ointment for the healing of chronic venous leg ulcers.


Sponsor

The Prince Charles Hospital

Enrollment

40 participants

Start Date

Dec 10, 2016

Study Type

Interventional

Conditions

Summary

The proposed research plans to examine the application of an ointment (Rectogesic 0.2% GTN), a pharmaceutical agent approved for human use, on venous leg ulcers. GTN ointment works in part by releasing nitric oxide (NO) into the wound, which acts to improve blood flow to the area and has the capacity to kill unwanted bacteria in the wound. The product to date has not been used routinely for the treatment of venous leg ulcers. A previous study by the chief investigator demonstrated the enzyme (iNOS), which drives the production of NO, was elevated in patients with faster healing leg ulcers, suggesting that application of a topical GTN donor (the ointment) might accelerate this healing process. The trial will be double blinded with half of the recruited patients receiving a placebo and the other half receiving the GTN donor. Neither the patients nor the research nurse involved in treatment will know if the product is the placebo or the GTN donor. The trial will run only for 4 weeks for each patient so rates of healing will be determined by planimetry (ulcer tracing) as complete healing of the ulcer will most likely not be achieved in the time frame being examined. If a statistically significant difference exists between the two groups the treatment will deemed successful. It is hoped that a subsequent larger trial will be planned based on the findings from this study. Hypothesis: Participants receiving the Rectogesic (GTN donor) will have a statistically higher linear healing rate (LHR) compared to patients that receive only the placebo.


Eligibility

Sex: Both males and femalesMin Age: 45 Yearss

Plain Language Summary

Simplified for easier understanding

This study is testing whether a medicated ointment containing glyceryl trinitrate (GTN) — the same ingredient found in some heart medications — can help heal venous leg ulcers when applied directly to the wound. GTN releases nitric oxide, which improves blood flow and may kill harmful bacteria. Half of patients will receive the real GTN ointment and half will receive a look-alike placebo ointment, and neither the patients nor the nurses treating them will know which one is which. You may be eligible if: - You are 45 years or older - You have been admitted to hospital with a venous leg ulcer (confirmed by your medical team) - Your ulcer is not caused by arterial disease, pressure, or diabetes You may NOT be eligible if: - Your ulcer is a malignant (cancer-related) ulcer - You have any type of active cancer - You have an active autoimmune disease or have had an organ transplant - You are having a sudden, severe worsening of heart disease (acute cardiac exacerbation) Talk to your doctor about whether this trial might be right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

The proposed research plans to examine the application of an ointment containing glyceryl trinitrate (GTN) [Rectogesic 0.2% GTN], a pharmaceutical agent approved for human use, on venous leg ulcers. G

The proposed research plans to examine the application of an ointment containing glyceryl trinitrate (GTN) [Rectogesic 0.2% GTN], a pharmaceutical agent approved for human use, on venous leg ulcers. GTN ointment works in part by releasing nitric oxide (NO) into the wound, which acts to improve blood flow to the area and has the capacity to kill unwanted bacteria in the wound. The product to date has not been used routinely for the treatment of venous leg ulcers. A previous study by the chief investigator demonstrated the enzyme (iNOS), which drives the production of NO, was elevated in patients with faster healing leg ulcers, suggesting that application of a topical GTN donor (the ointment) might accelerate this healing process. The trial will be double blinded with half of the recruited patients (n=20) receiving a placebo ointment and the other half receiving the GTN donor ointment (n=20). Neither the patients nor the research nurse involved in treatment will know if the product used is the placebo or the GTN donor ointment. Participants will receive 4 x weekly dressings (weekly for 4 weeks) for the ulcer, which will include an application of the randomised ointment (5-10mL depending on the size of the ulcer) and standardised usual care (e.g. compression bandaging or similar) as prescribed. All dressings will be undertaken by the research nurse in the hospital setting, with participants as inpatients in a hospital ward, or if discharged, as outpatients in a home or clinic setting. Participants will be referred to their GP for usual treatment at the completion of the 4 weekly treatments if their ulcer is not healed. Rates of healing will be determined by planimetry (ulcer tracing) using computer software for the purpose (Pictzar) since complete healing of the ulcer will most likely not be achieved in the time frame being examined. If a statistically significant difference exists between the two groups the treatment will deemed successful. It is hoped that a subsequent larger trial will be planned based on the findings from this study.


Locations(1)

The Prince Charles Hospital - Chermside

QLD, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12616000520437